HIGHLIGHTS
- who: Bing Wang and colleagues from the Anhui Medical University, China have published the article: The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus, in the Journal: (JOURNAL)
- what: In recent years, the research on PD-1 immune checkpoint has focused on its transcriptional and, post-transcriptional regulation. Its disease evaluation and disease relief have always been the research focus of clinicians and scientists. The authors propose that PD-1 and sPD-1 may be potential biomarkers for predicting SLE disease activity.
SUMMARY
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.